Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to block deadly tetanus after dirty wounds

NCT ID NCT07633119

Prevention Sponsor: Sinovac Life Sciences Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called SNA02-48 to see if it can prevent tetanus in people who have had a high-risk wound, like a deep cut or puncture from a dirty object. About 600 adults will receive either the new injection or the standard treatment (human tetanus immunoglobulin). The main goal is to measure whether the body produces enough protective antibodies against tetanus.

Why investors are watching

Sinovac Biotech Ltd. is running a Phase 3 trial through its subsidiary, Sinovac Life Sciences Co., Ltd., testing whether its injection SNA02-48 can prevent tetanus as well as the standard treatment, Human Tetanus Immunoglobulin. For a small-cap company, a successful Phase 3 result in a 600-patient prevention trial could validate a new product line and expand its vaccine portfolio beyond its existing business.

If it works: A positive result could mean SNA02-48 becomes a viable alternative to the current standard, giving Sinovac a new product to sell in a market where tetanus prevention is routine. That could strengthen the company's revenue base and its position in infectious disease prevention.

If it fails: Phase 3 trials often fail or show no advantage over the active control, and a negative or delayed readout could set back the product's development and hurt the company's prospects. Investors should expect uncertainty until the data are released.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males or females aged 18 years and above; 2. Participants who can understand and voluntarily sign the informed consent form; 3. Participants with high-risk tetanus exposure; 4. Participants of childbearing potential and their sexual partners voluntarily adopt effective contraceptive measures from the time the participant signs the informed consent form until 6 months after administration, with no plans for sperm or egg donation. Exclusion Criteria: 1. Suspected or confirmed tetanus ; 2. A history of previous tetanus infection; 3. A known history of 3 or more doses of tetanus toxoid or vaccines containing tetanus toxoid, or fewer than 3 previous doses but with the last dose of tetanus toxoid or vaccines containing tetanus toxoid administered within 6 months prior to the administration of the investigational product; 4. Known hypersensitivity to the investigational product (including excipients, HTIG, and other therapeutic monoclonal antibodies), or suffering from severe allergic diseases that, in the investigator's judgment, may impair the participant's safety; Other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tetanus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

tetanus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tetanus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, 212013, China

  • Affiliated Hospital of Yangzhou University

    Yangzhou, Jiangsu, 225000, China

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, 563000, China

  • Affiliated Nanhua Hospital, University of South China

    Hengyang, Hunan, 421010, China

  • Beijing Tiantan Hospital Affiliated to Capital Medical University

    Beijing, Beijing Municipality, 100070, China

  • Guangzhou Eighth People's Hospital, Guangzhou Medical University

    Guangzhou, Guangdong, 510440, China

  • Linfen Central Hospital

    Linfen, Shanxi, 041000, China

  • Lishui Central Hospital

    Lishui, Zhejiang, 323020, China

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, 545200, China

  • Liuzhou Worker's Hospital

    Liuzhou, Guangxi, 545000, China

  • Longhua District People's Hospital of Shenzhen

    Shenzhen, Guangdong, 518100, China

  • Ningbo Medical Center Li Huili Hospital

    Ningbo, Zhejiang, 315000, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, 100044, China

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, 337000, China

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, 030032, China

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, 518025, China

  • Taihe County People's Hospital

    Fuyang, Anhui, 236699, China

  • Taizhou People's Hospital

    Taizhou, Jiangsu, 225300, China

  • The Fifth Affiliated Hospital of Southern Medical University

    Guangzhou, Guangdong, 510900, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510120, China

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, 230601, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330008, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, 050000, China

  • The Third Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510150, China

  • Weifang People's Hospital

    Weifang, Shandong, 261000, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

  • Wuhan Union Hospital

    Wuhan, Hubei, 430022, China

  • Yuncheng Central Hospital, Shanxi Province

    Yuncheng, Shanxi, 044099, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.